https://holmusk.com

HolmuskHolmusk SOLUTIONSPUBLICATIONSPARTNERSCAREERSNEWSABOUTVISIONCOMPANYFOUNDING STORYVALUESTEAMABOUTAbout UsHolmusk is building the largest Real-World Evidence platform, starting with behavioral health. We are on a mission to reinvent behavioral health and transform lives through Real-World Evidence, AI-powered analytics, and digital solutions.VisionCompanyValuesTeamCONTACT USREAL-WORLD DATASoftwareCLINICAL EXPERTISECreating the standard for behavioral healthwith best-in-class real-world evidenceBehavioral health needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms or quality of care for behavioral health conditions, making innovation in the field difficult to achieve.We know that real-world data and analytics can revolutionize the behavioral health landscape by unlocking new and much-needed evidence to guide decisions for successful treatment development, efficient care delivery, and improved patient outcomes.That's why we've built the field's largest, most robust source of clinical data for real-world data and a uniquely powerful evidence engine. We're ready to set the standard for behavioral health.GET STARTEDBack to topContact usOUR DATAReal-World Evidence for
Real-World impactThe leading real-world data source for behavioral health The NeuroBlu Database enables researchers to build robust patient cohorts and conduct studies at an unprecedented level of granularity. Representing over 1 million patients, the NeuroBlu Database provides a single source of truth for the lived experiences of patients receiving behavioral health care across the U.S.1,300,000+patients30+geographically-diverse health systems20+years of longitudinal dataLongitudinalFollow patients over time with over 20 years of data spanning inpatient and outpatient sites, including hospitals, emergency rooms, and community psychiatry clinicsRichAdd valuable context to your research with data that have been enriched and transformed into research-ready variables using our first-in-kind natural language processing models developed specifically for behavioral healthComprehensiveTrack patient function and outcomes and make comparisons across different groups of patients with standardized quantitative outcome measuresBehavioral Health Conditions•Substance use disorders 485K+ patients•Major depressive disorder 350K+ patients•Bipolar disorder 184K+ patients•Attention-deficit/hyperactivity disorder 115K+ patients•Adjustment disorders100K+ patients•Post-traumatic stress disorder86K+ patients•Generalized anxiety disorder 80K+ patients•Borderline personality disorder65K+ patients•Schizophrenia61K+ patients•Panic disorder27K+ patients•and moreBehavioral Health Assessments•Brief Bipolar Disorder Symptom Scale (BDSS)•Brief Negative Symptom Assessment (BNSA)•Clinical Global Impressions (CGI-I/CGI-S)•Columbia-Suicide Severity Rating Scale (C-SSRS)•Global Assessment of Functioning (GAF)•Patient Health Questionnaire-9 (PHQ-9)•Positive Symptom Rating Scale (PSRS)•The Daily Living Activities–20 (DLA-20)•The Quick Inventory of Depressive Symptomatology (QIDS)•and morePharmacological Treatments•Antidepressants•Antipsychotics•Anxiolytics•Hypnotics and sedatives•Mood stabilizers•Psycholeptics•Psychostimulants•and moreLEARN MOREOUR DATAReal-World Evidence for
Real-World impactGold-standard data, elevated evidenceWe have captured and mapped de-identified data from patient electronic health records across the U.S. to create NeuroBlu Data, a single source of truth that reflects how behavioral health care is delivered. This data powers NeuroBlu Analytics, Holmusk's evidence engine that enables researchers to build patient cohorts, conduct studies at an unprecedented level of granularity, and generate impactful evidence.41,000,000+Patients50State coverage20+Years of longitudinal dataLongitudinalFollow patients over time with over 20 years of data, spanning inpatient and outpatient sites, including hospitals, emergency rooms, and community psychiatry clinics.Fit-for-purposeConduct observational studies with data that are curated and ready to address your most challenging research questions.ComprehensiveTrack patient functioning and outcomes and compare different groups of patients with standardized quantitative outcome measures.Behavioral health conditionsMajor depressive disorder11.7M+ patientsSubstance use disorder9.9M+ patientsGeneralized anxiety disorder6.5M+ patientsAttention deficit hyperactivity disorder5.1M+ patientsPost-traumatic stress disorder2.2M+ patientsBipolar I disorder514K+ patientsSchizophrenia493K+ patientsObsessive compulsive disorder448K+ patientsSchizoaffective disorder393K+ patientsBipolar II disorder457K+ patientsBorderline personality disorder244K+ patientsBehavioral health assessmentsNeuroBlu Data provides both composite scores for the below measures and responses for individual items within the scoring tools, enabling more granular research. Brief Bipolar Disorder Symptom Scale (BDSS)Brief Negative Symptom Assessment (BNSA)Clinical Global Impressions (CGI-I/CGI-S)Columbia-Suicide Severity Rating Scale (C-SSRS)Global Assessment of Functioning (GAF)Patient Health Questionnaire-9 (PHQ-9)Positive Symptom Rating Scale (PSRS)The Daily Living Activities–20 (DLA-20)The Quick Inventory of Depressive Symptomatology (QIDS)Pharmacological treatmentsNeuroBlu Data contains information on both psychotherapy and pharmacologic treatments. These include:AntidepressantsAntipsychoticsAnxiolyticsHypnotics and sedativesMood stabilizersPsycholepticsPsychostimulantsEnriched data for deeper clinical contextNeuroBlu Data is enriched through the application of natural language processing models—the first to be developed specifically for behavioral health. These models extract important information from unstructured clinical notes within the electronic health record and transform it into standardized measures, adding valuable context to research by making more fit-for-purpose data available than ever before.SymptomsGain a comprehensive picture of patients' emotions, cognition, and behaviors with data on symptoms that are often not captured in the electronic health record, such as anhedonia for patients with major depressive disorder.External stressorsExplore how life events and psychosocial environmental stressors impact patient outcomes and influence treatment response. Social determinants of healthBetter understand how social, relational, and occupational factors may impact behavioral health.OUR SolutionsHolmusk offers a range of digital solutions aimed at harnessing real-world data to improve behavioral health. Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges. NeuroBlu: Impactful insights powered by real-world dataAnalytics softwareAccess insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.Clinical expertiseConduct analysis within NeuroBlu Analytics alongside our team of clinical and data science experts, who will guide you through the design and execution of an end-to-end study tailored specifically to your organization's needs.Independently explore the database and build your own projects from the ground up.Access insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.Collaborate with our team of clinical and data science experts to create and conduct an end-to-end study tailored specifically to your organization's needs.Build your own environment supported by NeuroBlu dataQuickly and easily derive insightsCo-build a completely customizable studyWith the NeuroBlu platform, get the power of data at your fingertips—whether you explore the data on your own or collaborate with our team on a custom study.DataIndependently explore the database and build your own projects from the ground up.Analytics SoftwareAccess insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.Custom AnalyticsCollaborate with our team of clinical and data science experts to create and conduct an end-to-end study tailored specifically to your organization's needs.LEARN MOREBehavioral Health Conditions, including•Substance Use Disorders: 255,000+ patients•Major Depressive Disorder: 251,000+ patients•Bipolar Disorder: 134,000+ patients•Attention-Deficit/Hyperactivity Disorder: 82,000+ patients•Post-Traumatic Stress Disorder: 63,000+ patients•Schizoaffective Disorder: 34,000+ patients•Schizophrenia: 33,000+ patients•Borderline Personality Disorder: 19,000+ patients•Autism Spectrum Disorder: 16,000+ patientsBehavioral Health Assessments•Clinical Global Impressions (CGI-I/CGI-S)•Columbia-Suicide Severity Rating Scale (C-SSRS)•Patient Health Questionnaire-9 (PHQ-9)•The Daily Living Activities–20 (DLA-20)•The Quick Inventory of Depressive Symptomatology (QIDS)•Brief Bipolar Disorder Symptom Scale (BDSS)•Positive Symptom Rating Scale (PSRS)•Brief Negative Symptom Assessment (BNSA)•Global Assessment of Functioning (GAF)Pharmacological Treatments•Antidepressants•Antipsychotics•Anxiolytics•Hypnotics and sedatives•Mood stabilizers•Psycholeptics•PsychostimulantsContact UsInformation on a wide variety of conditions, such as:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsAccess to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsAccess to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsIndependently explore the database and build your own projects from the ground up.Access insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.Collaborate with our team of clinical and data science experts to create and conduct an end-to-end study tailored specifically to your organization's needs.Build your own environment supported by NeuroBlu dataQuickly and easily derive insightsCo-build a completely customizable studyRequest A DemoDigital solutions to better leverage real-world dataMake informed, data-driven decisions with our Management and Supervision Tool (MaST), a clinical decision support tool used in the U.K. that leverages data visualization and predictive analytics to prioritize individuals at risk of crisis and improve caseload management.LEARN MOREBehavioral Health Conditions, including•Substance Use Disorders: 255,000+ patients•Major Depressive Disorder: 251,000+ patients•Bipolar Disorder: 134,000+ patients•Attention-Deficit/Hyperactivity Disorder: 82,000+ patients•Post-Traumatic Stress Disorder: 63,000+ patients•Schizoaffective Disorder: 34,000+ patients•Schizophrenia: 33,000+ patients•Borderline Personality Disorder: 19,000+ patients•Autism Spectrum Disorder: 16,000+ patientsBehavioral Health Assessments•Clinical Global Impressions (CGI-I/CGI-S)•Columbia-Suicide Severity Rating Scale (C-SSRS)•Patient Health Questionnaire-9 (PHQ-9)•The Daily Living Activities–20 (DLA-20)•The Quick Inventory of Depressive Symptomatology (QIDS)•Brief Bipolar Disorder Symptom Scale (BDSS)•Positive Symptom Rating Scale (PSRS)•Brief Negative Symptom Assessment (BNSA)•Global Assessment of Functioning (GAF)Pharmacological Treatments•Antidepressants•Antipsychotics•Anxiolytics•Hypnotics and sedatives•Mood stabilizers•Psycholeptics•PsychostimulantsContact UsInformation on a wide variety of conditions, such as:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsAccess to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsAccess to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:•Substance use disorders: 255k+ patients•Major depressive disorder: 251k+ patients•Bipolar disorder: 134k+ patients•Attention-deficit/hyperactivity disorder: 82k+ patients•Post-traumatic stress disorder: 63k+ patients•Schizoaffective disorder: 34k+ patients•Schizophrenia: 33k+ patients•Borderline personality disorder: 19k+ patients•Autism spectrum disorder: 16k+ patientsLEARN MORELearn MoreCollaborate with our team of clinical and data science experts to create and conduct an end-to-end study tailored specifically to your organization’s needs.Learn MoreOUR VALUEReal-World Evidence for
Real-World impactCollaborating across the behavioral health ecosystemOur solutions have been leveraged by a range of stakeholders who share our vision that better evidence can vastly improve behavioral health.Life sciencesProvidersPayersGovernment & regulatorsAcademiaR&D for drug developmentOptimize trial design by leveraging data on symptoms and outcomes (e.g. CGI-S) to identify patients in the real world who meet study criteriaValidate design assumptions by tracking real-world outcomes of patient cohortsIdentify additional diagnoses as potential new targets for existing drugsMedical affairsCharacterize disease burden of specific sub-cohorts of behavioral health patientsGenerate evidence to illustrate existing gaps in treatment and how new drugs of interest help bridge these gapsIdentify patients best suited for newly approved or launched drugsMarket access and health economics & outcomes researchObtain advanced characterization of factors that may inhibit success, such as predictors of poor outcomes, lack of tolerability, and adherence to treatmentUnderstand optimal positioning of new products or lifecycle management of existing products to inform communication to payers and health care providersIdentify patient segments that are eligible for new drugs and use real-world outcomes to inform formulary decision-makingPayers and value-based careMonitor behavioral health utilization to optimize management strategies and understand patient journeysTrack and analyze patient outcomes over time and assess the effectiveness of different treatments and interventionsIdentify high-risk patients with predictive analytics for early interventionsR&D for drug developmentOptimize trial design by leveraging data on symptoms and outcomes (e.g. CGI-S) to identify patients in the real world who meet study criteriaValidate design assumptions by tracking real-world outcomes of patient cohortsIdentify additional diagnoses as potential new targets for existing drugsMedical affairsCharacterize disease burden of specific sub-cohorts of behavioral health patientsGenerate evidence to illustrate existing gaps in treatment and how new drugs of interest help bridge these gapsIdentify patients best suited for newly approved or launched drugsMarket access and health economics outcomes researchObtain advanced characterization of factors that may inhibit success, such as predictors of poor outcomes, lack of tolerability, adherence to treatment, etc.Better understand optimal positioning of new products or lifecycle management of existing products to inform communication to payers and health care providersIdentify patient segments that are eligible for new drugs and use real-world outcomes to inform formulary decision-makingPayors and value-based careMonitor behavioral health utilization with NeuroBlu to optimize management strategies and understand patient journeysTrack and analyze patient outcomes over time and assess the effectiveness of different treatments and interventionsIdentify high-risk patients with NeuroBlu's predictive analytics for early interventionsHolmusk has been recognized for innovation in behavioral health by:See How We CollaborateOUR WORK IN ACTIONFollow the latest evolutions in real-world evidencePublicationsExplore recent peer-reviewed publications and conference abstracts that leverage NeuroBlu Data to share new real-world evidence with the scientific community.Read MoreNewsCatch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.Read MoreThought leadershipCurious about the latest developments in real-world evidence and mental health? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.Read MoreStay Up to DateWe’d love for you to come along on the journey of improving behavioral health with better evidence. Holmusk is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:I agree to receive other communications from Holmusk.In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.I agree to allow Holmusk to store and process my personal data.You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.Thank you! We will get back to you soon.Oops! Something went wrong while submitting the form.SingaporeNew YorkLondonBasel© 2015-2026 HolmuskTerms & ConditionsPrivacy PolicyOur Work in ActionRead More PublicationsConference AbstractThe Weight of Mental Illness in the US: Obesity Burden and GLP-1 Receptor Agonist Treatment Inequalities in Mental Health CareMarch 27, 2026Conference AbstractMonitoring for abnormal movements associated with tardive dyskinesia in routine care: a retrospective analysis of electronic health recordsMarch 26, 2026Conference AbstractNatural language processing assisted chart review of patients with suspected or diagnosed clozapine induced myocarditis (CIM)March 25, 2026INNOVATION & INSIGHTSRead MoreCurious about what’s happening in the real-world evidence space? Check out our blog, the Hol Picture, where we share takeaways from recent talks and weigh in on news involving real-world evidence and behavioral health.PublicationsExplore recent peer-reviewed publications and conference abstracts that leveraged NeuroBlu data to share new real-world evidence with the scientific community.Read MoreNewsCatch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.Read MoreThought LeadershipCurious about the latest developments in real-world evidence and mental health? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.Read MoreStay Up-to-DateWe’re making fast strides toward a reimagined future for behavioral health, and we’d love for you to come along on our journey.Holmusk is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:I agree to receive other communications from Holmusk.In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.I agree to allow Holmusk to store and process my personal data.You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.Thank you! We will get back to you soon.Oops! Something went wrong while submitting the form.enen1777115881https://holmusk.com

ތިޔަ ސައިޓް އެޑިޓް ކުރަންވީތަ؟

ތިބާ ކީއްކުރަނީ؟